# EU-1-17-1263_public-assessment-report_20180220_20180220_efavirenz-emtricitabine-tenofovir-disoproxil-krka-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
14 December 2017
EMA/846772/2017
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
International non-proprietary name: efavirenz / emtricitabine / tenofovir
disoproxil
Procedure No. EMEA/H/C/004274/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
Table of contents
1. Background information on the procedure
5
1.1. Submission of the dossier
5
1.2. Steps taken for the assessment of the product
7
2. Scientific discussion
7
2.1. Introduction
7
2.2. Quality aspects
8
2.2.1. Introduction
8
2.2.2. Active substance
8
2.2.3. Finished medicinal product
13
2.2.4. Discussion on chemical, and pharmaceutical aspects
17
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
17
2.2.6. Recommendation(s) for future quality development.
17
2.3. Non-clinical aspects
17
2.3.1. Introduction
17
2.3.2. Ecotoxicity/environmental risk assessment
17
2.3.3. Discussion on non-clinical aspects
18
2.3.4. Conclusion on the non-clinical aspects
18
2.4. Clinical aspects
18
2.4.1. Introduction
18
2.4.2. Pharmacokinetics
19
2.4.3. Pharmacodynamics.
24
2.4.4. Post marketing experience
24
2.4.5. Discussion on clinical aspects
24
2.4.6. Conclusions on clinical aspects
25
2.5. Risk management plan
26
2.6. Pharmacovigilance
35
2.7. Product information
35
2.7.1. User consultation
35
3. Benefit-risk balance
36
4. Recommendation.
36
Assessment report
EMA/846772/2017
Page 2/38
